Researchers suggest their approach has the potential to transform early disease detection and health monitoring across diverse clinical settings.
New Johns Hopkins research shows an AI-driven liquid biopsy analyzing genome-wide cfDNA fragment patterns can detect early ...
Study shows iMDx test equivalent to NGS kits for dd-cfDNA measurement in kidney transplant patients, supporting future commercialization efforts. Results from a head-to-head comparison show iMDx's ...
Add Yahoo as a preferred source to see more of our stories on Google. A new study from UCLA Health and the University of Queensland reveals a blood test that can detect ALS using cell-free DNA ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, ...
Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...
A blood-based test using cell-free DNA had high sensitivity for colorectal cancer, high specificity for advanced neoplasia, and some sensitivity for advanced precancerous lesions. A blood-based ...
Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...
A new study may finally change how amyotrophic lateral sclerosis (ALS) is diagnosed. Scientists from UCLA Health and the University of Queensland developed a blood test that can spot signs of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results